Evidence map›Paper›PMID 23935463›Full record

ArticlePLoS medicine2013

Risk prediction for breast, endometrial, and ovarian cancer in white women aged 50 y or older: derivation and validation from population-based cohort studies.

Ruth M Pfeiffer, Yikyung Park, Aimée R Kreimer, James V Lacey, David Pee, Robert T Greenlee, Saundra S Buys, Albert Hollenbeck, Bernard Rosner, Mitchell H Gail and 1 more

2 registry-linked trialsAbstract read
In one paragraph

Article in PLoS medicine, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 95 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
95citing papers in PubMed, 4 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05651282 phase4completednot on this mapstarted 2023, after this paper: background citation

Uterine Cancer Risk Reducing Strategies in Postmenopausal Women

TypeinterventionalSponsorUniversity of British ColumbiaRan2023 to 2025Enrolled96ConditionsEndometrium CancerArmsProvera
NCT06268626 recruitingnot on this mapstarted 2024, after this paper: background citation

Non-Invasive Strategies for Early Detection of Uterine Cancer in Patients With Abnormal Uterine Bleeding

TypeobservationalSponsorUniversity of British ColumbiaRan2024 to 2027Enrolled1,000ConditionsEndometrial Cancer
3 · Its place in the literature

Who cites it

95 citing papers in PubMed, 4 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Review
  6. Article
  7. Improving ovarian cancer risk assessment using a machine learning model developed on data from the Prostate Lung Colorectal Ovarian Cancer Screening Trial.International journal of gynecological cancer : official journal of the International Gynecological Cancer Society · 2026
    Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Association ofTurkish journal of obstetrics and gynecology · 2025
    Article
  14. Breast cancer: pathogenesis and treatments.Signal transduction and targeted therapy · 2025
    Review
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article

35 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors.

Ruth M PfeifferDivision of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, United States of America. Pfeiffer@mail.nih.gov
Yikyung Park
Aimée R Kreimer
James V Lacey
David Pee
Robert T Greenlee
Saundra S Buys
Albert Hollenbeck
Bernard Rosner
Mitchell H Gail
Patricia Hartge

Funding

Risk prediction methodsZIACP010188 · NCI · DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS · PI ALBERT, PAUL · 2010 to 2025
$8.9M
Intramural NIH HHS
6 · The paper itself

Abstract

backgroundBreast, endometrial, and ovarian cancers share some hormonal and epidemiologic risk factors. While several models predict absolute risk of breast cancer, there are few models for ovarian cancer in the general population, and none for endometrial cancer. METHODS AND

findingsUsing data on white, non-Hispanic women aged 50+ y from two large population-based cohorts (the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial [PLCO] and the National Institutes of Health-AARP Diet and Health Study [NIH-AARP]), we estimated relative and attributable risks and combined them with age-specific US-population incidence and competing mortality rates. All models included parity. The breast cancer model additionally included estrogen and progestin menopausal hormone therapy (MHT) use, other MHT use, age at first live birth, menopausal status, age at menopause, family history of breast or ovarian cancer, benign breast disease/biopsies, alcohol consumption, and body mass index (BMI); the endometrial model included menopausal status, age at menopause, BMI, smoking, oral contraceptive use, MHT use, and an interaction term between BMI and MHT use; the ovarian model included oral contraceptive use, MHT use, and family history or breast or ovarian cancer. In independent validation data (Nurses' Health Study cohort) the breast and ovarian cancer models were well calibrated; expected to observed cancer ratios were 1.00 (95% confidence interval [CI]: 0.96-1.04) for breast cancer and 1.08 (95% CI: 0.97-1.19) for ovarian cancer. The number of endometrial cancers was significantly overestimated, expected/observed = 1.20 (95% CI: 1.11-1.29). The areas under the receiver operating characteristic curves (AUCs; discriminatory power) were 0.58 (95% CI: 0.57-0.59), 0.59 (95% CI: 0.56-0.63), and 0.68 (95% CI: 0.66-0.70) for the breast, ovarian, and endometrial models, respectively.

conclusionsThese models predict absolute risks for breast, endometrial, and ovarian cancers from easily obtainable risk factors and may assist in clinical decision-making. Limitations are the modest discriminatory ability of the breast and ovarian models and that these models may not generalize to women of other races. Please see later in the article for the Editors' Summary.

Indexed as

AgedBreast NeoplasmsCohort StudiesEndometrial NeoplasmsFemaleHumansIncidenceMiddle AgedModels, BiologicalOvarian NeoplasmsProspective StudiesRisk AssessmentROC CurveSEER ProgramUnited States

Identifiers

PMID23935463
PMCPMC3728034

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.